« FDA Approvals - Genzyme gets US FDA marketing nod for Renvela (PharmaBiz) Genzyme | Main | FDA Approvals - ATS Medical Receives FDA Clearance For ATS Simulus Semi-Rigid Annuloplasty »

FDA Issues Early Communication About an Ongoing Safety Review of


FDA Issues Early Communication About an Ongoing Safety Review of Aprotinin Injection
The U.S. Food and Drug Administration (FDA) issued an Early Communication about an Ongoing Safety Review of Aprotinin Injection (marketed as Trasylol), a drug used to control bleeding during heart surgery.
 

©2006 FDA-News.com. All rights reserved.